Family offices · United States
Jim Simons' Family Office: Euclidean Capital Explained
Euclidean Capital LLC is the New York family office of the late Renaissance Technologies founder Jim Simons and his wife, Marilyn Simons, who were its owners and managers according to its 2021 SEC filings. Ashvin Chhabra became its president in 2015 and was named as president and chief investment officer in 2021 SEC filings and by Institutional Investor in 2023. Jim Simons died in May 2024, according to the Simons Foundation; no figure for the office's total assets has been published. [1, 2, 3, 4, 5]
At a glance
| Family | Simons family |
|---|---|
| Founded | Not found |
| Headquarters | New York, New York, USA |
| Run by | Ashvin Chhabra, president and chief investment officer (as of 2023, Institutional Investor) |
| Size | No public figure; US-listed stocks of US$107.7 million (Institutional Investor, 2023) |
| Structure | Delaware LLC owned and managed by Jim and Marilyn Simons (SEC filings, 2021) |
| Known for | Investing the Simons family's money; biotechnology stakes such as PMV Pharmaceuticals |
How did Euclidean Capital start?
In July 2015 Bloomberg reported, as cited by Chief Investment Officer magazine, that Euclidean Capital, the family office of Renaissance Technologies founder James Simons, had hired Ashvin Chhabra, then chief investment officer of Merrill Lynch Wealth Management, as president from September 2015. Institutional Investor reported in February 2023 that, according to a person close to the firm, Simons launched Euclidean as he stepped down as chief executive of Renaissance in 2010. Jim Simons died on 10 May 2024 in New York City, at 86, according to the Simons Foundation. [1, 4, 5]
Reported by the sources named, not confirmed by an official source.
Who runs Euclidean Capital?
Schedule 13G filings made by Euclidean with the SEC in 2021 say that Jim and Marilyn Simons are its owners and managers and that Ashvin Chhabra is its president, chief investment officer and manager; they were signed for Euclidean by Joseph Cosmai as manager. Institutional Investor described Chhabra as president and chief investment officer in February 2023, and a speaker biography on the Sohn Conference Foundation site still lists him in those roles. Who leads the office in 2026, after Jim Simons' death, was not confirmed from a filing or a major outlet. [2, 3, 4, 6]
How big is Euclidean Capital?
No figure for the office's total assets has been published. In February 2023 Institutional Investor reported that the ten US-listed stocks in Euclidean's latest quarterly SEC filing were worth US$107.7 million, which it said was likely only part of the fund, and that the office had 23 employees. [4]
Reported by the sources named, not confirmed by an official source.
What does Euclidean Capital invest in?
Institutional Investor reported in February 2023 that the US-listed holdings Euclidean discloses were mostly biotechnology companies, many without revenue, with 23andMe the largest at about US$29 million. Schedule 13G filings show Euclidean and investment vehicles it manages holding 9.3% of PMV Pharmaceuticals at 31 December 2020 and 5.4% in a filing of October 2021. [2, 3, 4]
Reported by the sources named, not confirmed by an official source.
How is Euclidean Capital set up and regulated?
Euclidean Capital LLC is a Delaware limited liability company. Its 2021 SEC filings gave its address as 160 Fifth Avenue, 9th Floor, New York, NY 10010, and said it is the manager of investment vehicles including Greenland A LLC and Greenland NFP LLC. Institutional Investor reported in 2023 that it discloses at least some of its public stock holdings in quarterly SEC filings; whether it relies on the SEC family office rule was not confirmed. [2, 3, 4]
What changed in 2025 and 2026?
No major change found in 2025 or 2026. []
